Stem cell therapy for chronic kidney disease
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a type of stem cell therapy can help people with chronic kidney disease caused by diabetes or high blood pressure. It aims to see if the treatment is safe and can slow kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have kidney damage caused by diabetes or high blood pressure.
- Your kidney function (eGFR) is between 15 and 60, and you have significant protein in your urine (UACR over 300).
- You are at least 18 years old.
- You don't have severe anemia, an active infection, cancer, or a history of organ transplant.
- You are not pregnant and do not plan to become pregnant in the next 3 months.
- You haven't taken part in another drug trial in the past 2 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a type of stem cell called mesenchymal stromal cells (Amimestrocel) can help people with diabetic kidney disease. It aims to see if the treatment is safe and can improve kidney function.
This research study tests an experimental treatment for people with chronic kidney disease who are not yet on dialysis. The goal is to see if the treatment is safe and how it affects kidney function.
This study tests whether a single infusion of stem cells from bone marrow is safe for people with chronic kidney disease (CKD). It aims to see if this treatment can help slow kidney function loss.
This trial tests whether stem cells from donated umbilical cords can safely help people with type 2 diabetes who also have kidney damage. It aims to see if this therapy can improve kidney function.
This study tests if a single infusion of stem cells from umbilical cord blood can slow kidney damage caused by type 2 diabetes. It may help preserve kidney function and reduce protein in the urine.
This trial tests whether using special cells called mesenchymal stem cells (MSCs) can help treat chronic active antibody-mediated rejection—a long-term rejection inside a kidney transplant. It is for kidney transplant patients who are experiencing this specific type of rejection.
Hear when a new Kidney Disease, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.